Denial Of Drug’s Fast Track Application Was Not An Error, D.C. Circuit Affirms
WASHINGTON, D.C. — The U.S. Food and Drug Administration’s denial of a pharmaceutical company’s application for a fast-track approval of its new drug was not arbitrary and capricious, the District of...To view the full article, register now.
Already a subscriber? Click here to view full article